ID   Hep-G2 A-1
AC   CVCL_VA32
SY   A-1
DR   cancercelllines; CVCL_VA32
DR   Wikidata; Q54882779
RX   PubMed=29481805;
CC   Population: Caucasian.
CC   Virology: Contains 2 head to tails stably integrated hepatitis B virus (HBV) of the A-genotype.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 14-05-18; Last updated: 05-10-23; Version: 13
//
RX   PubMed=29481805; DOI=10.1016/j.bbrc.2018.02.175;
RA   Ogura N., Ogawa K., Watashi K., Ito T., Wakita T.;
RT   "Novel stable HBV producing cell line systems for expression and
RT   screening antiviral inhibitor of hepatitis B virus in human hepatoma
RT   cell line.";
RL   Biochem. Biophys. Res. Commun. 498:64-71(2018).
//